Cancer Immunol Res. 2025 Aug 1. doi: 10.1158/2326-6066.CIR-24-0897. Online ahead of print. ABSTRACT Advanced sarcomas have dismal outcomes in children and adults, with limited therapeutic options. While chimeric antigen receptor T cells (CAR-T) hold promise for treating advanced sarcomas, it is constrained by a paucity of effectual targets. Our previous clinical study identified endoglin (ENG/CD105), … Read more
Cancer Immunol Res. 2025 Aug 1;13(8):1131. doi: 10.1158/2326-6066.CIR-13-8-WWR. NO ABSTRACT PMID:40746082 | DOI:10.1158/2326-6066.CIR-13-8-WWR
Cancer Immunol Res. 2025 Jul 31. doi: 10.1158/2326-6066.CIR-24-0534. Online ahead of print. ABSTRACT Pancreatic adenocarcinoma (PDAC) has a dismal survival rate due to limited effective therapies. While studies have focused on innate immune cell influence on adaptive immune cell functions, few have explored interactions between innate immune cells, which modulate the unique PDAC tumor microenvironment … Read more
Cancer Immunol Res. 2025 Jul 31. doi: 10.1158/2326-6066.CIR-24-0853. Online ahead of print. ABSTRACT Despite the effectiveness of anti-programmed death 1 (PD-1)/PD-1 ligand 1 monoclonal antibodies against various cancers, resistance remains a significant issue among patients. The immunosuppressive T cell immunoreceptor with Ig and ITIM domains (TIGIT)/CD155 axis has emerged as a key mechanism contributing to … Read more
Cancer Immunol Res. 2025 Jul 30. doi: 10.1158/2326-6066.CIR-24-0919. Online ahead of print. ABSTRACT Therapies using natural killer (NK) cells that express chimeric antigen receptors (CAR-NKs) have been successfully employed against hematological malignancies. However, solid tumors resist CAR NKs partly by enriching tumor microenvironments with ligands for NK cell inhibitory receptors. Although the NK inhibitory receptor … Read more
Cancer Immunol Res. 2025 Jul 18. doi: 10.1158/2326-6066.CIR-24-1146. Online ahead of print. ABSTRACT Tumor-associated macrophages (TAMs) are key regulators of tumor immunity. With advances in single-cell analyses, SPP1+ TAMs have been observed across multiple tumor sites. However, their clinical relevance and phenotypic characteristics in clear cell renal cell carcinoma (ccRCC) have not been comprehensively delineated. … Read more
Cancer Immunol Res. 2025 Jul 8. doi: 10.1158/2326-6066.CIR-24-0532. Online ahead of print. ABSTRACT Tyrosine kinase inhibitors (TKIs) are initially efficacious against anaplastic lymphoma kinase (ALK) fusion gene-positive lung adenocarcinoma (ALK+ LUAD), but acquired resistance inevitably occurs. Therefore, alternative treatment strategies are needed for TKI-resistant cases. Although the use of immune checkpoint inhibitors (ICIs) has improved … Read more
Cancer Immunol Res. 2025 Jul 8. doi: 10.1158/2326-6066.CIR-24-1285. Online ahead of print. ABSTRACT Vγ9Vδ2 (TCRVγ9+ TCRVδ2+) T cells are promising immunotherapeutic targets with effective antitumor properties in both in vitro and preclinical models of triple-negative breast cancer (TNBC). However, no information regarding their potential role in the context of human TNBC progression and response to … Read more
Cancer Immunol Res. 2025 Jul 2. doi: 10.1158/2326-6066.CIR-25-0103. Online ahead of print. ABSTRACT Tumor-associated macrophages (TAMs) and regulatory T cells (Tregs) are major immune components of the tumor microenvironment, promoting tumor growth and limiting the efficacy of chemotherapy in almost all cancer indications. While Tregs are well known for their immune suppressive activity toward the … Read more
Cancer Immunol Res. 2025 Jul 2. doi: 10.1158/2326-6066.CIR-25-0034. Online ahead of print. ABSTRACT Dendritic cell (DC) based-vaccines remain the sole approved cancer vaccine. Despite their established safety and efficacy in numerous trials against cancers and infections, long-term clinical benefits have been modest. Most trials have employed DCs derived from blood monocytes (MoDC), but emerging evidence … Read more
